与间歇性肺部疾病 (PH-ILD) 相关的肺高血压:回到未来
Giordano Fiorentù1, Nicol Bernardinello2, Giacomo Giulianelli1
1Departement of Cardiac, Thoracic, Vascular Science and Public Health, University of Padova, Padua, Italy.
Advances in therapy
|February 19, 2025
概括
在间歇性肺病 (PH-ILD) 中的肺高血压会使患者的结果恶化. 吸入式特雷普罗斯尼尔对PH-ILD治疗具有前景,为管理这种严重疾病提供了新的希望.
科学领域:
- 心脏病学和肺病学.
- 药理学研究 药理学研究
- 间歇性肺部疾病 (ILD) 管理管理
背景情况:
- 肺高血压 (PH) 是一种渐进的疾病,增加了肺动脉的压力,往往使慢性肺病复杂化.
- 世卫组织第3组PH包括COPD-PH和PH-ILD等子类别,PH-ILD预后最差.
- 间歇性肺病 (ILD) 会导致不可逆转的呼吸系统衰退,同时存在的PH会加剧症状并降低生活质量.
研究的目的:
- 审查PH-ILD.目前和未来的药理管理策略.
- 批判性地讨论二次性到间歇性肺部疾病的PH的治疗景观.
- 突出最近的进展和PH-ILD的潜在治疗方法.
主要方法:
- 对PH-ILD.现有文献和临床试验数据的审查.
- 对世卫组织3组PH的当前治疗指南的分析.
- 对INCREASE试验的批判性讨论,以及吸入特雷普罗斯尼尔在PH-ILD中的作用.
主要成果:
- 在ILD患者中通过心声学,亲BNP和右心导管检测PH的早期检测至关重要.
- 目前的指导方针强调优化呼吸系统治疗和长期氧气治疗,以治疗呼吸系统疾病的PH.
- 在INCREASE试验中,在PH-ILD治疗中,吸入特雷普罗斯尼尔的潜在益处得到了证明,这为新的治疗途径提供了新的治疗途径.
结论:
- 在患有间歇性肺病的患者中,PH-ILD显著恶化了预后和生活质量.
- 虽然传统治疗侧重于潜在的呼吸道疾病,但PH-ILD的药理选择有限.
- 吸入式特雷普罗斯尼尔在PH-ILD的药理管理中是一个有前途的发展,需要进一步研究.
相关概念视频
01:30Pulmonary Hypertension: Classification and Pathogenesis
147
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
147
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
165
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
165
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
145
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
145
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
127
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
127
01:20COPD: Pathogenesis and Clinical Features
226
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
226